inflammationjoint-healthpain-relief

Boswellia

Boswellia is one of the best-studied herbs for joint pain, with good evidence for osteoarthritis. AKBA's 5-LOX inhibition makes it a complementary approach to COX-inhibiting NSAIDs. Take with fat for best absorption and allow 4–8 weeks.

Boswellia (Indian frankincense) is studied for its anti-inflammatory effects. NCCIH notes that some research suggests boswellia may help reduce symptoms of osteoarthritis and other inflammatory conditions. MSK says AKBA (acetyl-11-keto-β-boswellic acid) is the most potent anti-inflammatory boswellic acid, inhibiting 5-lipoxygenase (5-LOX) and reducing leukotriene synthesis. Evidence for joint pain relief is among the most robust of any herbal supplement.

Where to get it

We earn a commission if you buy through these links. It doesn't change your price. How we make money

Top pick Amazon.ca Shop Amazon.ca

Search Amazon.ca for boswellia products.

Traditional & historical use

Boswellia serrata has been used in Ayurvedic medicine for over 3,000 years under the name 'Shallaki.' It was used for arthritis, inflammatory bowel disease, asthma, and skin conditions. The resin (frankincense) from the related species Boswellia sacra has been burned ceremonially in the Middle East and North Africa for millennia.

Active compounds & mechanisms

Key compounds: AKBA (acetyl-11-keto-β-boswellic acid), KBA (11-keto-β-boswellic acid), α-boswellic acid, β-boswellic acid, incensole acetate, luteolic acid, boswellic acid esters, terpenes

AKBA is the most potent boswellic acid. It specifically inhibits 5-lipoxygenase (5-LOX), the enzyme that synthesises pro-inflammatory leukotrienes. Unlike NSAIDs, boswellic acids do not inhibit COX-1 or COX-2, which means less risk of gastric irritation and renal side effects. Boswellic acids also reduce NF-κB transcription factor activity, lowering the production of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6). They additionally inhibit cartilage-degrading enzymes (matrix metalloproteinases), potentially slowing cartilage breakdown in osteoarthritis. AKBA is poorly absorbed without fat; formulations combining it with lecithin or phospholipids (e.g., Phytosome) significantly improve bioavailability.

Research & evidence

Strong support Some support Weak or no supportColours show how well the sources back each point. The reason is next to each one.

Boswellia significantly reduces knee pain and stiffness in people with osteoarthritis.

Moderate evidenceSome support. Based on one or a few small trials

Study details

Multiple randomised controlled trials show boswellia extract reduces pain and improves function in osteoarthritis of the knee more than placebo, with effects seen in 4–8 weeks.

AKBA inhibits 5-lipoxygenase (5-LOX), reducing leukotriene synthesis in inflammatory pathways.

Moderate evidenceSome support. Based on one or a few small trials

Study details

MSK notes AKBA is the most potent boswellic acid and specifically inhibits 5-LOX, reducing production of leukotrienes that drive inflammation in arthritis and inflammatory bowel disease.

Boswellia may reduce symptoms of ulcerative colitis and Crohn's disease.

Limited evidenceSome support. The source hedges (“may” or “associated with”)

Study details

Some clinical trials suggest boswellia extract can reduce IBD activity scores, though evidence quality is variable and it is not a standard treatment.

Boswellia reduces radiographic edema in brain tumour patients and may have neuroprotective properties.

Limited evidenceSome support. The source hedges (“may” or “associated with”)

Study details

A randomised trial showed boswellia reduced cerebral edema in patients with brain tumours receiving radiotherapy; this is a specific clinical context but supports anti-inflammatory CNS activity.

Mental health notes

Some emerging research suggests boswellic acids may have neuroprotective effects through anti-inflammatory pathways. Incensole acetate, a component of Boswellia resin, has been studied for anxiolytic effects in animals by activating TRPV3 channels, though human evidence is very limited.

Gut health notes

Boswellia has been studied for inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis. NCCIH notes that some research suggests boswellia may help reduce symptoms of IBD, though evidence is limited.

Dosage

FormAmount
Capsule300–500 mg of boswellia extract (standardised to 60–65% boswellic acids, or ≥10% AKBA) 2–3 times daily; most clinical trials use 900–1,200 mg/day in divided doses; take with fat for improved AKBA absorption
Dosage varies by body weight, age, and condition severity. Standardised extracts with AKBA content stated on the label are preferred over unstandardised powders. Take with a meal containing fat to improve AKBA absorption. Results take 4–8 weeks. Consult a healthcare provider before use if you have liver disease, are pregnant, or take immunosuppressants.

Side effects

Generally well tolerated. Mild GI symptoms are the main side effect and improve with food. Not a rapid pain reliever — effects build over weeks.

Well documented Reported (case reports, anecdotal or one study) None reportedThe circle shows how well documented an effect is, not how serious it is. A rarely reported effect can still be serious, so always read ‘When to stop’.

EffectFrequencyWhen to stop
Nausea and GI upsetWell documentedListed plainly by NIH, MSK or LiverToxNot statedStop and talk to a doctor if you notice any unexpected or concerning symptoms.
DiarrhoeaWell documentedListed plainly by NIH, MSK or LiverToxNot statedStop and talk to a doctor if you notice any unexpected or concerning symptoms.
Skin rashWell documentedListed plainly by NIH, MSK or LiverToxNot statedStop and talk to a doctor if you notice any unexpected or concerning symptoms.
Acid refluxWell documentedListed plainly by NIH, MSK or LiverToxNot statedStop and talk to a doctor if you notice any unexpected or concerning symptoms.

Safety & interactions

Safety

NCCIH states that boswellia is generally well tolerated in clinical studies. MSK notes most adverse effects are mild GI symptoms. It is generally considered safe for up to 6 months in studies. A Boswellia serrata extract called H15 has been used for decades in Germany. The most common side effects are nausea, diarrhoea, and abdominal pain. NCCIH notes that little is known about the safety of boswellia use in pregnancy and breastfeeding.

Contraindications

Avoid during pregnancy without healthcare provider approval, as boswellia may stimulate uterine contractions. Use caution in people with active GI ulcers or significant GI disease. People with liver disease should consult a healthcare provider. If you take blood thinners, NSAIDs, or immunosuppressants, see Drug interactions.

Drug interactions

NSAIDs (ibuprofen, naproxen, aspirin)Theoretical

Boswellia has complementary anti-inflammatory mechanisms to NSAIDs (inhibiting 5-LOX rather than COX). The combination may have additive effects on inflammation. The combination is generally considered safe, but the additional anti-inflammatory effect may need monitoring by a healthcare provider.

Immunosuppressants (methotrexate, cyclosporine)Theoretical

Boswellia may have immunomodulatory effects. Concurrent use with immunosuppressants should be discussed with a healthcare provider, particularly in autoimmune conditions.

Anticoagulants and antiplatelet agentsTheoretical

Limited evidence suggests boswellic acids may have mild antiplatelet effects. Combining with warfarin or antiplatelet medications may slightly increase bleeding risk. Consult a healthcare provider.

Established: stated plainly by an authoritative source. Documented: supported by case reports or trial data. Theoretical: based on mechanism, animal data, or a cautious listing. Always check with your pharmacist or prescriber.

Related

Was this page useful? Rate it · Report a mistake